| 1 | therdose pharma pvt ltd | | | | | | | 2 | 1.06% |
| 2 | of various therapeutic areas | | | | | | | 1 | 0.53% |
| 3 | versed in development of | | | | | | | 1 | 0.53% |
| 4 | well versed in development | | | | | | | 1 | 0.53% |
| 5 | is well versed in | | | | | | | 1 | 0.53% |
| 6 | rd is well versed | | | | | | | 1 | 0.53% |
| 7 | inhouse rd is well | | | | | | | 1 | 0.53% |
| 8 | strong inhouse rd is | | | | | | | 1 | 0.53% |
| 9 | our strong inhouse rd | | | | | | | 1 | 0.53% |
| 10 | filing with emerging markets | | | | | | | 1 | 0.53% |
| 11 | with emerging markets in | | | | | | | 1 | 0.53% |
| 12 | emerging markets in the | | | | | | | 1 | 0.53% |
| 13 | various therapeutic areas utilizing | | | | | | | 1 | 0.53% |
| 14 | molecules across the domain | | | | | | | 1 | 0.53% |
| 15 | development of complex drug | | | | | | | 1 | 0.53% |
| 16 | spectrum of various therapeutic | | | | | | | 1 | 0.53% |
| 17 | wide spectrum of various | | | | | | | 1 | 0.53% |
| 18 | a wide spectrum of | | | | | | | 1 | 0.53% |
| 19 | across a wide spectrum | | | | | | | 1 | 0.53% |
| 20 | products across a wide | | | | | | | 1 | 0.53% |
| 21 | markets in the oncology | | | | | | | 1 | 0.53% |
| 22 | in the oncology therapeutic | | | | | | | 1 | 0.53% |
| 23 | the oncology therapeutic area | | | | | | | 1 | 0.53% |
| 24 | aim to develop differentiated | | | | | | | 1 | 0.53% |
| 25 | we aim to develop | | | | | | | 1 | 0.53% |
| 26 | oncology we aim to | | | | | | | 1 | 0.53% |
| 27 | in oncology we aim | | | | | | | 1 | 0.53% |
| 28 | in development of complex | | | | | | | 1 | 0.53% |
| 29 | dossiers been supported for | | | | | | | 1 | 0.53% |
| 30 | a specialization in oncology | | | | | | | 1 | 0.53% |
| 31 | therdose has developed more | | | | | | | 1 | 0.53% |
| 32 | global clientele 40 dossiers | | | | | | | 1 | 0.53% |
| 33 | various global clientele 40 | | | | | | | 1 | 0.53% |
| 34 | dossiers have been filed | | | | | | | 1 | 0.53% |
| 35 | have been filed across | | | | | | | 1 | 0.53% |
| 36 | been filed across 25 | | | | | | | 1 | 0.53% |
| 37 | and specialty drugs to | | | | | | | 1 | 0.53% |
| 38 | generics and specialty drugs | | | | | | | 1 | 0.53% |
| 39 | 35 generics and specialty | | | | | | | 1 | 0.53% |
| 40 | than 35 generics and | | | | | | | 1 | 0.53% |